Search results
Making new medicines for people with serious diseases. Regeneron is a leading biotechnology company that seeks to invent, develop and commercialize life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine ...
Our goal is to address serious medical conditions across multiple and diverse therapeutic areas. Our pipeline is powered by end-to-end research and development capabilities, and our commitment to operational excellence and patient safety ensures we consistently produce the highest-quality medicines.
Monitor SARS-CoV-2 variants with Regeneron’s COVID-19 Dashboard. Refreshed daily with new genomes and associated patient metadata. Learn how Regeneron is actively working on testing existing medicines and developing new antibodies to combat the COVID-19 pandemic.
2 days ago · TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Society of Gene and Cell Therapy (ASGCT) annual conference in Baltimore, Maryland, from May 7 to 11, 2024. Data from 10 abstracts ...
Mar 23, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the ...
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business update.
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024 Mar 25 Regeneron Provides Update on Biologics License Application for Odronextamab
